Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

By A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David H. Johnson. New England Journal of Medicine, 2006

5,863 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1f1cd5e6590d16ff4e0ca4c0f0a87c16ab5d38f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer (2011, background): “for some patients, engender a drive towards novel molecular-targeting agents [ 46-48 ].”
The resurgence of platinum-based cancer chemotherapy (2007, background): “But it has subsequently been shown to significantly improve responses and survival of patients with non-small-cell lung cancer when added to carboplatin–paclitaxel combination chemotherap”
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “• Findings of two randomised clinical trials revealed that bevacizumab improves OS when combined with paclitaxel/carboplatin regimens in patients with NSCC and PS 0–1 and, therefore, may be offered in the absence of contraindications in eligible patients with advanced NSCC (bevacizumab should be giv”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “92) 2 [86]”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “In non-squamous non-small cell lung cancer (NSCLC), the ECOG E4599 study reported increased response rates on incorporating bevacizumab with paclitaxel and carboplatin, accompanied by significantly improved PFS and OS 81 (TABLE 1) , resulting in FDA regulatory approval in October 2006.”
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line Paclitaxel/carboplatin ± bevacizumab NCT00021060 [32] Improvement in PFS and OS”